GFM
OCUL icon

GF Fund Management’s Ocular Therapeutix OCUL Stock Holding History

GF Fund Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.5K Buy
4,784
+599
+14% +$5.71K ﹤0.01% 423
2025
Q4 		$50.8K Buy
4,185
+442
+12% +$5.37K ﹤0.01% 405
2025
Q3 		$43.8K Sell
3,743
-283
-7% -$3.38K ﹤0.01% 409
2025
Q2 		$37.4K Hold
4,026
– – ﹤0.01% 445
2025
Q1 		$29.5K Buy
4,026
+725
+22% +$5.57K ﹤0.01% 461
2024
Q4 		$28.2K Buy
+3,301
New +$32.2K ﹤0.01% 438

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GF Fund Management's OCUL Position: Q1 2026 in Review

GF Fund Management increased its Ocular Therapeutix (OCUL) stake by 14% in Q1 2026, buying an estimated $5.71K and bringing the position to 4,784 shares worth $40.5K. The position accounts for ﹤0.01% of the portfolio, ranked #423.

GF Fund Management first reported a position in OCUL in Q4 2024 and has held it in 6 quarters since. The position peaked at $50.8K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • GF Fund Management held 4,784 shares of Ocular Therapeutix worth $40.5K as of Q1 2026.
  • GF Fund Management bought 599 Ocular Therapeutix shares in Q1 2026, an estimated $5.71K.
  • Ocular Therapeutix made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #423 holding.
  • GF Fund Management first reported a position in Ocular Therapeutix in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Ocular Therapeutix position peaked at $50.8K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.